Valentis, Inc. Offer to Purchase for Cash 16,940 Shares of Its Series A Preferred Stock and 55% of Common Stock Purchase Warrants, Class A and Common Stock Purchase Warrants, Class BValentis Inc • May 10th, 2002 • Biological products, (no disgnostic substances)
Valentis, Inc., a Delaware corporation ("Valentis", the "Company", "us" or "we"), is a biopharmaceutical company that converts genomic discoveries into medicines. The Company has three product platforms for the development of novel therapeutics: the GeneMedicine, GeneSwitch and OptiPEG platforms. The Del-1 GeneMedicine therapeutic is the lead product for the GeneMedicine platform of non-viral gene delivery technologies. Del-1 is an angiogenesis gene that is being developed for peripheral arterial disease and ischemic heart disease. The EpoSwitch therapeutic for anemia is the lead product for the GeneSwitch platform. The EpoSwitch product is being developed to allow control of erythropoietin protein production from an injected gene by an orally administered drug. The OptiPEG platform, consisting of proprietary PEGylation technologies, allows for improved dosing of biopharmaceuticals. OptiPEG is being developed through licensing to partners.
